Page last updated: 2024-12-11

vofopitant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6918331
CHEMBL ID522302
SCHEMBL ID310338
MeSH IDM0269922

Synonyms (26)

Synonym
gr-205171
n-((2-methoxy-5-(5-(trifluoromethyl)-1h-tetrazol-1-yl)phenyl)methyl)-2-phenyl-3-piperidinamine
gr205171
3-piperidiamine, n-((2-methoxy-5-(5-(trifluoromethyl)-1h-tetrazol-1-yl)phenyl)-methyl)-2-phenyl-, (2s-cis)-
(2s,3s)-3-((2-methoxy-5-(5-(trifluoromethyl)-1h-tetrazol-1-yl)benzyl)amino)-2-phenylpiperidine
vofopitant [inn]
gr 205171
(2s,3s)-n-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine
vofopitant
CHEMBL522302
168266-90-8
k08bk043ys ,
unii-k08bk043ys
bdbm50408664
bdbm50419354
3-piperidinamine, n-((2-methoxy-5-(5-(trifluoro-methyl)-1h-tetrazol-1-yl)phenyl)methyl)-2-phenyl-
vofopitant [who-dd]
gtpl5752
SCHEMBL310338
DB12436
Q21098911
HY-12142
CS-0003109
DTXSID10870099
xilnrortjvdyrh-hkuynngssa-n
AKOS040740555

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study of casopitant concentration in plasma."( A pharmacokinetic PET study of NK₁ receptor occupancy.
Bani, M; Cunningham, VJ; Fernandes, SA; Gomeni, R; Gunn, RN; Rabiner, EA; Ratti, E; Zamuner, S, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" The antiemetic efficacy of NK1 receptor antagonists against chemotherapy-induced emesis is, however, enhanced when combined with a 5-HT3 receptor antagonist."( Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Clemes, SA; House, F; Palmer, JL; Reid, K; Somal, HS; Stott, JR; Troakes, C; Wright, RJ, 2000
)
0.31
"The enhancement of NK1 receptor antagonist antiemetic activity through combination with a 5-HT3 receptor antagonist is not replicated in motion-induced nausea."( Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Clemes, SA; House, F; Palmer, JL; Reid, K; Somal, HS; Stott, JR; Troakes, C; Wright, RJ, 2000
)
0.31
" The present findings suggest that NK1 receptor antagonists, when combined with a SSRI, augment 5-HT release by modulating substance P/5-HT interactions in the dorsal raphe nucleus."( Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice.
De Felipe, C; Froger, N; Gardier, AM; Guiard, BP; Guilloux, JP; Hunt, SP; Lanfumey, L; Przybylski, C; Seif, I, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
"0 mg/kg doses, 30 min before testing produced anxiolytic-like effects in an increasing dose-response manner as measured by the percentage of open arm time and percentage of open arm entries."( Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.
Corsi, M; Davis, M; Heldt, SA; Ratti, E; Ressler, KJ; Trist, D, 2009
)
0.35
" Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study of casopitant concentration in plasma."( A pharmacokinetic PET study of NK₁ receptor occupancy.
Bani, M; Cunningham, VJ; Fernandes, SA; Gomeni, R; Gunn, RN; Rabiner, EA; Ratti, E; Zamuner, S, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)IC50 (µMol)0.00010.00000.09526.8130AID208406
Substance-P receptorHomo sapiens (human)Ki0.00010.00000.79368.7470AID350133
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1346346Human NK1 receptor (Tachykinin receptors)1996Regulatory peptides, Aug-27, Volume: 65, Issue:1
GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.
AID350135Inhibition of GR-73632-induced foot tapping in po dosed Mongolian gerbil assessed as duration of repetitive hind foot tapping administered 1 hr before GR-73632 challenge2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
AID77134Inhibition of resiniferatoxin-induced systemic vascular leakage in guinea pig (SYVAL) upon oral administration at 24 hr r1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID76983Inhibition of resiniferatoxin-induced systemic vascular leakage in guinea pig (SYVAL) upon oral administration at 1 hr1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID208406Displacement of [125I]-labeled SP from the human Tachykinin receptor 1 expressed in CHO cells1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID350133Displacement of [3H]substance P from human recombinant NK1 receptor expressed in CHO cells2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (21.13)18.2507
2000's43 (60.56)29.6817
2010's12 (16.90)24.3611
2020's1 (1.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.74 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (11.27%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (88.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vestipitant and Vofopitant 2 Day PSG Study for Insomnia [NCT00606697]Phase 251 participants (Actual)Interventional2007-12-19Completed
Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects [NCT00907985]Phase 112 participants (Actual)Interventional2009-05-15Terminated(stopped due to Slow recruitment; trial unlikely to reach completion)
Evaluation of the Efficacy of the NK1 Antagonist GR205171 in Posttraumatic Stress Disorder [NCT00383786]Phase 247 participants (Actual)Interventional2006-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00383786 (1) [back to overview]Changes in CAPS Scores.

Changes in CAPS Scores.

"The Clinician-Administered PTSD Scale (CAPS) is the gold standard in PTSD assessment. The CAPS is a 30-item structured interview that corresponds to the DSM-IV criteria for PTSD. This is a 17-item core symptom scale, measuring both frequency and intensity of symptoms, with the most frequently used scoring rule is to count a symptom as present if it has a frequency of 1 or more and an intensity of 2 or more. A PTSD diagnosis is made if there is at least 1 B symptom, 3 C symptoms, and 2 D symptoms as well as meeting the other diagnostic criteria. Scores range from 0-136 0 (best possible outcome) to 136 (worst possible outcome). The relevant time-points for reporting change were at baseline and 8 weeks." (NCT00383786)
Timeframe: Baseline, 8 weeks

Interventionscores on a scale (Mean)
GR20517143.5
Placebo51.1

[back to top]